Editorial 2 : Delhi HC Rejects Semaglutide Patent Suit
Context:
Delhi High Court allowed Dr. Reddy’s Laboratories to manufacture and export generic semaglutide, rejecting Novo Nordisk’s patent infringement plea, citing concerns of evergreening.
Introduction:
Semaglutide, a GLP-1 receptor agonist, is a breakthrough drug for Type 2 diabetes and obesity, marketed by Novo Nordisk as Ozempic and Wegovy. While the original composition patent has expired, the company held a formulation patent to extend its monopoly. The Delhi HC’s ruling in favor of DRL highlights India’s commitment to balancing patent protection and public health, preventing undue extension of drug monopolies through evergreening.
Key Details of the Case:
- Drugs and Patents Involved:
- Semaglutide is a GLP-1 receptor agonist marketed as Ozempic (diabetes) and Wegovy (weight loss).
- Novo Nordisk held two main Indian patents:
- Patent No. 275964: Composition patent, expired in September 2024.
- Patent No. 262697: Formulation/delivery patent, expiring March 2026.
- DRL challenged the second patent on grounds of lack of novelty and inventive step, arguing that minor modifications did not constitute a new invention.
- Legal Arguments:
- Novo Nordisk: Claimed formulation was novel and exhibited significantly higher efficacy.
- DRL: Contended the second patent represented evergreening, prohibited under Section 3(d) of the Indian Patents Act, 1970, as it lacked true innovation.
- Delhi HC’s Ruling:
- Court allowed DRL to continue manufacturing and exporting semaglutide.
- Recognized DRL’s challenge as prima facie valid, indicating potential double patenting by Novo Nordisk.
- Stressed that sales in India remain restricted until the original patent expires.
Relevant Key Issues:
- Patent Law and Public Interest:
- Section 3(d) prevents evergreening, ensuring innovations are genuine and not mere modifications.
- Protects affordable access to essential medicines, aligning with India’s constitutional duty under Article 47 (Duty to raise public health standards).
- Impact on Indian Pharma Industry:
- Encourages generic drug production, strengthening India’s position as the “pharmacy of the world”.
- Promotes competition, reducing costs for life-saving drugs in domestic and international markets.
- Opens opportunities for companies like Cipla, Sun Pharma, and Mankind Pharma to introduce GLP-1 drugs, expanding healthcare access.
- Global Pharmaceutical Governance:
- Highlights India’s balanced approach between intellectual property rights (TRIPS compliance) and public health priorities.
- Demonstrates judicial intervention as a check on corporate monopolies, ensuring that patents do not unduly extend market exclusivity.
- Science & Technology Angle:
- GLP-1 drugs represent advanced biotechnology, targeting insulin secretion, glucagon inhibition, and appetite suppression.
- Access to generics can enhance diabetes and obesity management, critical given India’s rising non-communicable disease burden.
Additional Perspective:
- Economic Significance:
- Affordable semaglutide could save costs for governments and consumers, reducing dependency on imported patented drugs.
- Generic exports contribute to India’s pharmaceutical trade surplus, reinforcing Make in India and Atmanirbhar Bharat initiatives.
- Health Policy Implications:
- Facilitates broader NCD control programs under National Health Mission.
- Aligns with WHO’s emphasis on generic access for essential medicines.
- Legal Precedent:
- Strengthens enforcement of Section 3(d) jurisprudence, already invoked in the Novartis Glivec case (2013).
- Sends a signal to multinational pharma about limiting evergreening practices in India.
Way Forward:
- Strengthen regulatory vigilance to prevent evergreening and promote genuine pharmaceutical innovation.
- Encourage domestic production and export of affordable generic drugs to enhance India’s global pharmaceutical footprint.
- Ensure wider patient access to essential medicines while maintaining incentives for innovation under TRIPS-compliant patent laws.
- Promote public awareness and policy frameworks supporting equitable healthcare and cost-effective treatment for non-communicable diseases.
Conclusion:
The Delhi HC ruling is a landmark decision reinforcing India’s commitment to public health over corporate monopolies, ensuring that genuine innovation is rewarded while preventing abuse of patent law. It provides a strategic boost to domestic pharmaceutical capacity, promotes affordable access to critical medicines, and reflects India’s balanced stance in global IP and trade dynamics.